Immunoassay Device Based on Acoustic Vortex Nanoparticle Enrichment
|
By LabMedica International staff writers Posted on 08 Feb 2017 |

Image: A sample of 500 nanometer particles in solution. In the top image, the acoustic whirlpool device was turned off. The bottom image shows that when the device was turned on, the nanoparticles were concentrated to the point of becoming visible as a dark line down the center of the chamber (Photo courtesy of Duke University).
An inexpensive acoustic transducer is the key to a novel immunoassay that may eventually be combined with a smartphone camera to form a platform for the rapid detection of diagnostic proteins in blood, urine, or saliva samples.
Investigators at Duke University developed an acoustic-fluidic chip capable of generating single vortex acoustic streaming inside a glass capillary through using low-power acoustic waves (only five volts was required). The single vortex acoustic streaming that was generated, in conjunction with the acoustic radiation force, was able to enrich submicrometer- and nanometer-sized particles in a small volume. Numerical simulations were used to clarify the mechanism of the single vortex formation and were verified experimentally, demonstrating the focusing of silica and polystyrene particles ranging in diameter from 80 to 500 nanometers.
In a proof-of-principle study, the acoustic-fluidic chip was used to perform an immunoassay in which nanoparticles that captured fluorescently labeled biomarkers were concentrated in a long, thin glass vial to enhance the emitted signal.
“Diagnosis impacts about 70% of healthcare decisions,” said senior author Dr. Tony Huang, professor of mechanical engineering and materials science at Duke University. “If we can improve the quality of diagnostics while reducing its costs, then we can tremendously improve the entire healthcare system. My goal is to create a small diagnostic device about the size of a cell phone that can autonomously separate biomarkers from samples. With this vortex technology, the biomarkers could then be concentrated enough to see with a simple camera like the ones found in today’s cellular phones.”
Investigators at Duke University developed an acoustic-fluidic chip capable of generating single vortex acoustic streaming inside a glass capillary through using low-power acoustic waves (only five volts was required). The single vortex acoustic streaming that was generated, in conjunction with the acoustic radiation force, was able to enrich submicrometer- and nanometer-sized particles in a small volume. Numerical simulations were used to clarify the mechanism of the single vortex formation and were verified experimentally, demonstrating the focusing of silica and polystyrene particles ranging in diameter from 80 to 500 nanometers.
In a proof-of-principle study, the acoustic-fluidic chip was used to perform an immunoassay in which nanoparticles that captured fluorescently labeled biomarkers were concentrated in a long, thin glass vial to enhance the emitted signal.
“Diagnosis impacts about 70% of healthcare decisions,” said senior author Dr. Tony Huang, professor of mechanical engineering and materials science at Duke University. “If we can improve the quality of diagnostics while reducing its costs, then we can tremendously improve the entire healthcare system. My goal is to create a small diagnostic device about the size of a cell phone that can autonomously separate biomarkers from samples. With this vortex technology, the biomarkers could then be concentrated enough to see with a simple camera like the ones found in today’s cellular phones.”
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








